At 6.8% CAGR, the North America Pulmonary Function Testing Systems Market is projected to be worth US$ 160.73 million by 2028, says Business Market Insights

According to Business Market Insights research, the North America pulmonary function testing systems market was valued at US$ 108.42 million in 2022 and is expected to reach US$ 160.73 million by 2028, registering a CAGR of 6.8% from 2022 to 2028. Rising incidence of lung-related disorders and workplace pulmonary function testing systems are the critical factors attributed to the North America pulmonary function testing systems market expansion.

Occupational lung disease is one of the most influential factors accelerating the demand for pulmonary function testing systems. As per The Johns Hopkins University 2023 report, repeated and long-term exposure to certain irritants on the job can lead to lung disease with long-lasting effects on the patients. For example, in certain occupations, people are more at risk of occupational lung diseases due to the nature of the location, work, and environment. Additionally, people working in a car garage or textile factory may be exposed to hazardous chemicals, dust, and fibers that result in lifetime lung problems if not diagnosed and treated. Moreover, asbestosis is caused by the inhalation of microscopic fibers of asbestos with disease progression and resulting in scarring of the lungs of people working in construction, manufacturing, and chemical refining. According to the American Lung Association, an estimated 1.3 million construction and industry workers are exposed to asbestos. Pulmonary function testing plays a critical role in determining occupational lung disease among workers. As per the American College of Occupational and Environmental Medicine 2020 report, spirometry in the occupational health setting plays a critical role in the primary, secondary, and tertiary prevention of workplace-related lung disease. The aim of workplace spirometry is to identify workers who require further evaluation for occupational lung-related disorders. As spirometry testing is intended for both screening and clinical evaluations at the workplace, it is performed in ranging from small clinical practices to small-sized industries to multiple plant medical departments within an industry. Further, to recognize the central role of spirometry in workplace respiratory programs, the American College of Occupational and Environmental Medicine (ACOEM) developed three spirometry position statements that advanced the occupational health practice.

For example, the US Occupational Safety and Health Administration (OSHA) issued its Best Practices Guidance on Spirometry Testing in Occupational Health Programs. Such an effective practice at the workplace has significant demand for pulmonary function testing systems during 2022-2028.

On the contrary, risk of cross-contamination and lack of skilled professionals hampers the North America pulmonary function testing systems market.

Based on type, the North America pulmonary function testing systems market is segmented into cart-based pft systems and stationery pft systems. The cart-based pft systems segment held 77.4% share of North America pulmonary function testing systems market in 2022, amassing US$ 83.96 million. It is projected to garner US$ 126.68 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on test type, the North America pulmonary function testing systems market is segmented into spirometry, lung volume, gas exchange testing, maximum voluntary ventilation, oxygen titration test, and others. The spirometry segment held 44.9% share of North America pulmonary function testing systems market in 2022, amassing US$ 48.67 million. It is projected to garner US$ 73.07 million by 2028 to expand at 7.0% CAGR during 2022–2028.

Based on component, the North America pulmonary function testing systems market is segmented into hardware, software, and services. The hardware segment held 41.9% share of North America pulmonary function testing systems market in 2022, amassing US$ 45.42 million. It is projected to garner US$ 66.82 million by 2028 to expand at 6.6% CAGR during 2022–2028. 

Based on application, the North America pulmonary function testing systems market is segmented into chronic obstructive pulmonary disorder, asthma, chronic shortness of breath, restrictive lung disease, and others. The chronic obstructive pulmonary disorder segment held 36.4% share of North America pulmonary function testing systems market in 2022, amassing US$ 39.49 million. It is projected to garner US$ 59.67 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on end-user, the North America pulmonary function testing systems market is segmented into hospitals, specialty clinics, and diagnostic laboratories. The hospitals segment held 46.9% share of North America pulmonary function testing systems market in 2022, amassing US$ 50.86 million. It is projected to garner US$ 76.97 million by 2028 to expand at 7.2% CAGR during 2022–2028.

Based on country, the North America pulmonary function testing systems market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.6% share of North America pulmonary function testing systems market in 2022. It was assessed at US$ 90.60 million in 2022 and is likely to hit US$ 135.53 million by 2028, exhibiting a CAGR of 6.9% during the forecast period.

Key players dominating the North America pulmonary function testing systems market are COSMED Srl; KoKo PFT Ltd; MGC Diagnostics Corp; Morgan Scientific Inc; ndd Medical Technologies Inc; PulmOne Advanced Medical Devices Ltd; Schiller AG; and Vyaire Medical Inc, and among others.

• In April 2021; Vyaire Medical announced the global launch of ArtiQ.PFT, an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). ArtiQ.PFT is the first cloud-based PFT-solution that leverages artificial intelligence.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com